The advent of BRAF-targeted therapies led to increased survival in patients with metastatic melanomas harboring a BRAF V600 mutation (implicated in 46-48% of malignant melanomas 
Introduction
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BRAF beta trials manuscript DRAFT 5 patients harboring the less common V600D, V600R, or V600M mutations may be treated successfully with vemurafenib or dabrafenib. [9] [10] [11] According to the European Society for Medical Oncology (ESMO), genotyping of the BRAF V600 mutational status is mandatory for metastatic melanoma patients. Several tests analyzing the BRAF mutational status are available. These tests include Sanger sequencing, pyrosequencing, next generation sequencing, immunohistochemistry, and tests based on realtime polymerase chain reaction (PCR), with each method having its own sensitivity, specificity, cost, and turnaround time. 12, 13 Sanger sequencing has for many years been considered the standard method for the detection of mutations from tumor DNA, but is hampered by low sensitivity. Immunohistochemistry is cheap and results are obtained within 48 hours, however the technique is highly specific for V600E and missing all other BRAF mutations. Pyrosequencing is highly sensitive although prone to errors without using customer-designed set-up. Real-time-PCR-based strategies are more sensitive compared to
Sanger, but commercial tests specifically designed for detecting V600E miss some of the less common V600 mutations. For example, the cobas ® 4800 BRAF V600 Mutation Test (Roche, Basel, Switzerland) shows only limited cross-reaction with V600E2 (≥65% mutation), V600K
(≥35% mutation), and V600D (≥10% mutation), and the therascreen BRAF RGQ PCR Kit (Qiagen, Venlo, the Netherlands) detects V600E, V600D, V600K, and V600R, but misses V600M. Next generation sequencing has high sensitivity and multiplexing options, allowing generation of a molecular profile of each tumor sample analyzed, but on the down side this technique is expensive and time consuming and generates a lot of information while only the BRAF mutational status is of interest. 12, 13 In general, current diagnostic tests for BRAF mutational status are labor-intensive requiring specialized staff and a complex infrastructure.
They are therefore often performed by a third party, which delays therapeutic decisions.
BRAF beta trials manuscript DRAFT 6 The Idylla TM can easily be performed on-site without needing extra molecular infrastructure or a highly skilled staff.
In the current multi-center study, archival FFPE tumor samples from melanoma patients were tested for BRAF mutational status using the Idylla TM BRAF Mutation Test. To establish test performance, the results were compared to the results previously obtained with routine reference methods.
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Materials and Methods
Samples
In the current multi-center study, In the current study, a number (i.e., mostly 1 or 2, up to 9) of 5 µm to 40 µm thick FFPE tissue sections were sampled as close as possible (within the FFPE block) to the tissue sections used to generate the reference result (see Supplementary Table 1) . Before the analyses started, the tumor content and area was determined on a hematoxylin-eosin (HE)-stained slide by a Pathologist. Based on the visual assessment of the HE staining of consecutive slides, appropriate macrodissection was performed before loading the cartridge to achieve a tumor cell content of at least 50%. These selected FFPE tissue sections were placed directly into the Idylla TM cartridge following the instructions for use. In each of the six study centers, two artificial FFPE samples (i.e., BRAF V600E and BRAF V600K FFPE Reference Standards; Horizon Diagnostics, Cambridge, UK) were included as external controls.
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Idylla
TM System
The Idylla TM molecular diagnostics platform (Biocartis, Mechelen, Belgium) is a randomaccess fully automated system providing sample to result functionality, based on allele- The mutant signal is considered valid if the ΔCq is within a validated range, and the sample will then be characterized as BRAF V600 mutation positive, indicating the specific mutation group. All samples with a valid wild-type signal but a ΔCq value outside the validated range are characterized as BRAF V600 mutation negative.
Sanger sequencing
Sanger sequencing was used as a routine reference method for a number of samples 
Commercial routine BRAF mutation tests used as reference method
The cobas ® 4800 BRAF V600 Mutation Test (Roche), BRAF RGQ PCR Kit (Qiagen), and BRAF StripAssay ® V600E (Viennalab, Vienna, Austria) were performed according to the manufacturer's instructions.
In-house routine BRAF mutation tests used as reference method
Wild-type blocking real-time PCR was performed on a LightCycler ® 480 real-time PCR instrument (Roche) using LightCycler ® 480 SYBR Green (Roche) to detect DNA amplification. Allele-specific real-time PCR was performed using dual-labeled probes on a cobas ® Z480 Analyzer (Roche) essentially as described before. 16 Digital droplet PCR was performed on a QX100 TM system (Bio-Rad Laboratories, Hercules, CA) according to the instructions of the manufacturer. High resolution melting analysis was performed on a LightCycler ® 480 (Roche Diagnostics, Vienna, Austria), with primers flanking a 177 bp amplicon of BRAF exon 15 encompassing the V600 codon; analysis of the melting curves was performed using the LightCycler ® 480 Gene Scanning Software (Roche).
Results
PCR curves
Representative examples of PCR curves and the corresponding Cq values for different Idylla TM analysis results are shown in Figure 1 .
Results of Idylla TM BRAF Mutation Test
The BRAF mutational status of 148 retrospective clinical FFPE samples of various tissues
from patients with melanoma was tested at six centers with the Idylla TM System (Idylla TM ),
i.e., the BRAF Mutation Test performed on the Idylla TM platform, and the results were compared with the original assessments made by several routine reference methods (Supplementary Table 1 ). Idylla TM results were not used for any diagnostic purposes.
The following routine reference methods were used: cobas ® 4800 BRAF V600 Mutation Test (Roche; n=40; the test result did not specify the exact nature of the detected mutation, but, as this test was designed to detect V600E, mutations detected were considered V600E for the analysis), BRAF RGQ PCR Kit (Qiagen; n=28), BRAF StripAssay ® V600E (Viennalab; n=1), Sanger sequencing (as only method n=29, combined with other method n=32), wildtype blocking real-time PCR (in house; n=14), allele-specific real-time PCR using duallabeled probes (in house; n=15), real-time PCR and high resolution melting (HRM) analysis (in house; n=22). To maximize sensitivity, tumor area was enriched by macrodissection in 79
cases. In 1 case, microdissection was applied after removal of paraffin and HE staining of the sections. Samples in which no tumor tissue was observed by staining and visual control were excluded from the data set.
Of the 148 FFPE samples analyzed, 70 tested positive for a V600E/E2/D mutation and 20
tested positive for V600K/R/M on Idylla TM , in 51 cases no mutation was found, and Idylla TM reported insufficient DNA input for 7 samples (Table 1) . Overall in the first assessment,
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Idylla TM demonstrated agreement with the routine reference methods in 126 samples. In 9
samples Idylla TM detected a mutation while no mutation was detected by the reference method, and in 2 cases Idylla TM did not detect the mutation observed by a reference method.
In 3 samples, different mutations were detected. The routine reference methods detected 71 V600E, 10 V600K, 1 V600R, and 1 V600M mutation. (Table 3) . Idylla TM detected another mutation as compared to the
BRAF beta trials manuscript DRAFT 13 one detected by the reference method in 3 samples, and detected a mutation while the reference method did not find a mutation in 10 samples (including 1 sample where the reference method failed due to insufficient DNA input). In 2 samples, the mutation detected by the reference method was not found by Idylla TM .
The In Sample 40, Idylla TM found V600E/E2/D, but the routine reference method failed due to insufficient DNA input. Therefore, 9 samples were removed from the dataset.
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Performance of the Idylla TM BRAF Mutation Test
Taking into account the additional concordant results and the samples removed from the dataset, Idylla TM results were in agreement with the confirmed test results from reference methods in 136 of 139 samples, resulting in an overall concordance of 97.84% (Table 4) .
Overall in the clinical FFPE samples, Idylla TM identified all the V600E or V600K mutations found by routine reference methods. In addition (as established by further analysis, see Table 3 ), Idylla TM found a mutation where the routine method did not in 7 cases, and identified a mutation different from the routine test result in 1 case.
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Discussion
During the last decade, the field of oncology has experienced large changes with the cancer biomarkers and personalized cancer therapy. Patient-personalized cancer therapies are now available for, e.g., lung cancer patients with mutated EGFR (erlotinib, gefitinib, and afatinib), 
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BRAF beta trials manuscript DRAFT 16 observed before when analyzing up to 31 years old FFPE tumor samples of a variety of human malignancies. 14, 15 Apart from detecting V600E, Idylla TM also enables reliable detection of V600D, V600K, V600R, and V600M. The V600K mutation constitutes 19% of the BRAF mutations in metastatic melanoma patients. 4 Patients with this mutation are eligible to vemurafenib and dabrafenib therapy but some routine BRAF tests do not detect all non-V600E mutations, e.g., the cobas ® 4800 BRAF V600 Mutation Test detects only 70% of V600K. 17 According to the Manufacturer's instructions accompanying the cobas ® 4800 BRAF V600 Mutation Test, a mutation was reported by cross-reactivity when V600D was present in more than 10% of the sampled DNA, V600K when present in more than 35%, and V600E2 when present in more than 65% of the sampled DNA. Therefore some patients that might benefit do not receive BRAF inhibitors when the current routine diagnostic tests are used, but would do if Idylla TM would be used to assess BRAF mutational status. Moreover, Idylla TM is also able to detect V600D, V600R, and V600M mutations that are implicated in the response to BRAF inhibitors as well. 9,10,18-22 In the current study, Idylla TM enabled detection of a V600K/R/M mutation while the reference method did not, in 6 samples.
Given the need for molecular pathology infrastructure and specialized staff, the routine reference methods are often performed by a third party. This results in longer turnaround times from sample to test result (days or weeks instead of hours), which could delay therapeutic decisions. In particular in the case of rapidly progressing diseases like advanced melanoma, such delays may negatively affect patient care, as a fast assessment of BRAF mutation status can be of critical importance. As Idylla TM can be easily implemented in any pathology laboratory setting and as the turnaround time to obtain test results is very short, the incorporation of the BRAF mutational status in the initial histological report is possible and targeted therapy can readily be initiated. Idylla TM has a sensitivity of 1% versus the 5% sensitivity for most PCR-based methods, including cobas ® 4800 BRAF V600 Mutation Test and versus 5-10% for Next Generation Sequencing methods. In 7 instances, no mutation was detected by the routine reference method but Idylla TM identified a V600E/E2/D or V600K/R/M mutation whose presence was confirmed when a third method was used; this might be due to the higher sensitivity, the capability to identify more mutations, and the standardized workflow of Idylla TM .
As Idylla TM Mutation Tests are always designed to qualitatively detect specific mutations, e.g., V600E/E2/D or V600K/R/M, they are not intended to determine all mutations within the exon or to quantify allelic frequency. Other more specialized molecular techniques should be utilized when complete overviews of all mutations present or when quantitative information would be needed. In general, the Idylla TM System was perceived to be very user-friendly, with very little hands-on time and short sample-to-result times being major advantages. The workflow (including deparaffinization, liberation of DNA, real-time PCR amplification, and target detection) is automated, and due to the set-up the risk of cross-contamination is minimal. At the down-side it was mentioned that DNA (or lysate) cannot be withdrawn from the cartridge and stored for future use.
In conclusion, the Idylla TM BRAF Mutation Test on the Idylla  TM platform enables b Allele-specific real-time PCR using dual-labeled probes (in house). A C C E P T E D M A N U S C R I P T
ACCEPTED MANUSCRIPT
BRAF beta trials manuscript DRAFT 30 
